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Hepatitis B e antigen–negative chronic hepatitis B
(e2CHB) has been reported in Asia but its prevalence and
clinical significance have not been determined. The aims of
this study were to determine the prevalence of e2CHB in
Hong Kong and the frequency of precore and core promoter
mutations in these patients. A cross-sectional study was
performed in 350 consecutive Chinese patients (230 men
and 120 women; mean age 6SD, 42 6 13 years) with
chronic hepatitis B virus infection. A total of 243 (69%)
patients were hepatitis B e antigen (HBeAg)-negative of
whom 15% had clinical cirrhosis. In the remaining 85% of
patients, 63% had normal and 22% had elevated transami-
nases. Serum hepatitis B virus (HBV) DNA was detectable
using branched DNA assay in 46% of HBeAg-negative
patients with clinical cirrhosis/elevated transaminases.
Forty-five percent of the patients with e2CHB had the
precore stop codon mutation, and an additional 41% had
core promoter changes. There was no correlation between
the presence of precore/core promoter mutations and liver
disease or HBV-DNA levels. Overall, 17% of HBeAg-negative
patients were viremic and had evidence of chronic liver
disease (e2CHB) with mean HBV-DNA levels comparable
with that in HBeAg-positive patients. In summary, we found
that e2CHB may be present in up to 17% of HBeAg-negative
patients seen in a tertiary referral center in Hong Kong.
e2CHB may be a heterogenous condition and is not
invariably associated with the precore HBV mutant. Popula-
tion studies are needed to determine the true prevalence of
e2CHB in Asia and to assess its natural course and
response to treatment. (HEPATOLOGY 2000;31:763-768.)
Seroconversion from hepatitis B e antigen (HBeAg) to e
antibody (anti-HBe) is usually accompanied by cessation of
hepatitis B virus (HBV) replication and remission of liver
disease.1,2 However, some HBeAg-negative patients remain
viremic and continue to have active liver disease.3-5 Many of
these patients are found to have a G to A change at nucleotide
1896 (A1896), which creates a premature stop codon in the
precore region of the HBV genome.6-11 This mutation pre-
vents the translation of the precore protein and completely
abolishes the production of HBeAg. Other patients have
mutations in the start codon of the precore region or
mutations in the core promoter region.9-15 The most common
core promoter mutations involve a 2-nucleotide substitution:
A to T at nucleotide 1762 and G to A at nucleotide 1764
(TA).12-15 In vitro studies showed that the TA changes decrease
transcription of precore messenger RNA and hence secretion
of HBeAg.16-19 Not all HBeAg-negative patients who are
viremic have mutations that affect the secretion of HBeAg.
Some continue to have low levels of wild type HBV.
The phenomenon of HBeAg-negative chronic hepatitis B
(e2CHB) (hepatitis B surface antigen positive, HBeAg nega-
tive, serum HBV DNA detected by non–polymerase chain
reaction [PCR] assay, and clinical/biochemical evidence of
liver disease) was initially thought to be rare and largely
confined to the Mediterranean basin. The prevalence of
e2CHB is now considered to have surpassed that of e1CHB
(hepatitis B surface antigen and HBeAg positive, serum HBV
DNA detected by non-PCR assay, and clinical/biochemical
evidence of liver disease) in some Mediterranean countries
although population studies have not been performed to
ascertain the relative frequency of e1 versus e2CHB. Several
factors may account for the changing epidemiology. First, in
the past decade, treatment of chronic hepatitis B has focused
on HBeAg-positive patients because it was initially thought
that HBeAg-negative patients have nonreplicative infection
and do not require antiviral treatment. More recently, studies
on interferon therapy in patients with e2CHB have reported
high relapse rates discouraging treatment of these pa-
tients.20-22 Second, transmission of HBV from patients with
e2CHB may be facilitated by a lower level of vigilance in
these patients23 or a higher level of replication of the e2 HBV
mutant. In vitro studies suggest that mutations in the precore
and/or core promoter region may increase the replication
capacity of HBV16,17,19 but clinical data comparing serum
HBV-DNA levels in patients with and without these muta-
tions are not available. Finally, it is possible that environmen-
tal changes in the last 1 to 2 decades may have favored the
selection of the e2 HBV mutants.
e2CHB has also been reported in the Middle East and in
Asia such as in Japan8,9,12,14 and Hong Kong11,15 but is
extremely rare in the United States.24,25 The prevalence of
e2CHB in different geographical regions is related to the
predominant HBV genotype because the occurrence of A1896,
the most common mutation associated with the HBeAg-
negative phenotype, is restricted to HBV genotypes with T at
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nucleotide 1858 (T1858).11,24,26,27 In our previous studies in
Hong Kong, we found that only 60% of Chinese patients who
had chronic HBV infection were infected with HBV genotypes
that have T185811,15 Of these, 87% to 100% had A1896 after
HBeAg seroconversion. However, not all HBeAg-negative
patients with A1896 had active liver disease. None of the
patients infected with HBV genotypes that have C at nucleo-
tide 1858 (C1858) developed A1896 after HBeAg seroconver-
sion but 91% had TA changes in the core promoter region.11,15
With the availability of new therapies for chronic hepatitis
B, knowledge of the prevalence of e2CHB may change our
treatment strategies and focus research on the safety and
efficacy of treatment for this expanding patient population.
The aims of this study were to determine the prevalence of
e2CHB in Hong Kong and the prevalence of precore and core
promoter mutations among these patients.
PATIENTS AND METHODS
We performed a cross-sectional study in 350 consecutive Chinese
patients with chronic HBV infection seen by a single hepatologist
(N.W.-Y.L.) in the Hepatitis and General Hepatology Clinics, Prince
of Wales Hospital, Hong Kong between December 1997 and June
1998. Patients who were coinfected with hepatitis C or D virus or
human immunodeficiency virus and patients with other concomi-
tant causes of chronic liver disease were excluded. The study
population included 230 (66%) men and 120 (34%) women, aged
12 to 80 years (mean 6 SD, 42 6 13 years). Fifteen patients had
previous antiviral treatment, 13 had interferon, 1 had famciclovir,
and 1 had sequential treatments with interferon, lamivudine, and
famciclovir. These patients were studied 1 to 120 months (median,
28 months) after the cessation of treatment. Patients who were
actively participating in clinical trials on antiviral therapy of chronic
hepatitis B were followed in a Research Clinic and were not included
in this study. Less than 10% of patients had liver biopsies. The
clinical status of the patients were stratified into three groups: Group
I included noncirrhotic patients with normal alanine transaminase
(ALT) levels, group II included noncirrhotic patients with elevated
ALT levels (.upper limit of normal), and group III included
patients with clinical evidence of cirrhosis. Among the 55 group III
patients, all had ultrasound findings suggestive of cirrhosis (coarse
liver architecture, nodular liver surface, and blunt liver edge) and
evidence of hypersplenism (splenomegaly on ultrasound and plate-
let count ,100,000/mm3). In addition, 15 had esophageal varices on
endoscopy and 4 had clinically detectable ascites.
All the patients were known to be HBsAg positive. All the patients
were tested for HBeAg, anti-HBe, and liver profile (serum albumin,
bilirubin, aspartate transaminase and ALT, and alkaline phosphatase
levels) during the clinic visit. An additional sample of blood was
drawn and tested for HBV DNA by the branched DNA (bDNA) assay
as well as by an in-house PCR assay. Samples that were HBV-DNA
positive by PCR were further studied to determine the core promoter
and precore HBV sequence.
Hepatitis B serological markers were tested using commercially
available enzyme-linked immunosorbent assay kits from Abbott
Laboratories (North Chicago, IL). Serum HBV DNA was quantified
using the bDNA assay (Quantiplex HBV DNA; Chiron Diagnostics,
Emeryville, CA) which has a detection limit of 7 3 105 viral
equivalents/mL.
PCR and direct sequencing of amplified products was performed
as described previously using primers that flanked the core pro-
moter and precore regions.15 The sensitivity limit of the PCR assay
was 500 viral equivalents/mL. This limit was determined by running
duplicate dilution series of HBV plasmids with known concentra-
tions and sera with known HBV-DNA levels based on the bDNA
assay. All necessary precautions were taken to avoid cross-
contamination during the PCR assay. Mutations were confirmed by
bidirectional sequencing.
Two-tailed Student’s t test was used to compare continuous
variables. Two-tailed x2 test with Yates correction was used to
compare categorical data. Mean HBV-DNA levels were compared
after logarithmic transformation of the HBV-DNA values in the
bDNA assay, and patients with undetectable HBV DNA in the bDNA
assay were excluded.
RESULTS
Characteristics of the Patients Studied. Our study population
included 107 (31%) HBeAg-positive and 243 (69%) HBeAg-
negative patients. The HBeAg-negative patients were signifi-
cantly older than the HBeAg-positive patients, mean ages 6
SD for the HBeAg-negative and the HBeAg-positive patients
being 45 6 12 years and 36 6 13 years, respectively (P ,
.001). The gender ratios in the HBeAg-positive (men/women,
68:39) and the HBeAg-negative (men/women, 162:81) pa-
tients were similar.
Clinical Status of the Patients. Fifty-five (16%) patients had
clinical cirrhosis. Of the remainder, 194 (55%) had normal
and 101 (29%) had elevated ALT levels. Patients with clinical
cirrhosis were significantly older than those without clinical
cirrhosis (P , .001) (Table 1). Among the noncirrhotic
patients, the mean ages of those with normal (group I) and
elevated (group II) ALT levels were similar.
Compared with HBeAg-positive patients, the HBeAg-
negative patients were more likely to have normal ALT levels,
63% (153 of 243) versus 38% (41 of 107) (P , .001), but the
proportions with clinical cirrhosis were similar, 15% (36 of
243) versus 18% (19 of 107) (Table 1).
Male patients were more likely to have elevated ALT levels,
34% (78 of 230) vs. 19% (23 of 120) (P 5 .006) and a higher
tendency to have clinical cirrhosis, 18% (42 of 230) versus
11% (13 of 120).
HBV-DNA Detection in Relation to HBeAg Status and Liver
Disease. Serum HBV DNA was detected in 39% (135 of 350)
using the bDNA assay and in 64% (223 of 350) using the
more sensitive PCR assay (Table 2). A significantly lower
TABLE 1. Clinical Status of Patients in Relation to HBeAg Status, Gender, and Age
Clinical Status Total
No. (%) of Patients
Sex M/F
Mean Age 6 SD
(yr)HBeAg1 HBeAg2
Noncirrhotic
Normal ALT (group I) 194 (55) 41 (38)* 153 (63)* 110 (57)/84 (43) 41 6 12†
Elevated ALT (group II) 101 (29) 47 (44) 54 (22) 78 (77)/23 (23) 40 6 13†
Clinical cirrhosis (group III) 55 (16) 19 (18) 36 (15) 42 (76)/13 (24) 52 6 14†
Total 350 107 243 230 (66)/120 (34) 42 6 13
*ABeAg-positive vs. HBeAg-negative patients in group I (P , .03).
†Group I or II vs. group III, P , .001.
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percent of HBeAg-negative patients had detectable HBV DNA
using the PCR assay: 53% (128 of 243) versus 89% (95 of
107) (P , .001) in HBeAg-positive patients. This difference
was more marked when HBV DNA was detected using the
bDNA assay: 21% (52 of 243) of HBeAg-negative versus 78%
(83 of 107) of HBeAg-positive patients had detectable HBV
DNA (P , .001) (Table 2). Among the patients who were
bDNA positive, the HBeAg-negative patients had significantly
lower HBV-DNA levels compared with the HBeAg-positive
patients, log10 mean 6 SD HBV-DNA levels being 6.98 6 0.78
versus 8.02 6 1.20 Eq/mL, respectively (P , .001) (Table 2,
Fig. 1). The difference in HBV-DNA levels between the
HBeAg-negative and HBeAg-positive patients was more
marked in group I (P , .001) than in the group II patients
(P , .03).
Among the HBeAg-negative patients, HBV-DNA detection
was strongly associated with the presence of liver disease
(Table 2). Using the bDNA assay, HBV DNA was detected in
the sera of only 7% (11 of 153) of patients in group I versus
46% (25 of 54) in group II (P , .001) and 44% (16 of 36) in
group III (P , .001). In addition, group I patients had the
lowest HBV-DNA levels (Table 2, Fig. 1). However, liver
disease or ALT levels could not be predicted by the serum
HBV-DNA levels because there was significant overlap among
the three groups.
Contrary to the HBeAg-negative patients, HBV DNA was
detected in similar proportions of groups I, II, and III
HBeAg-positive patients. Moreover, HBeAg-positive group I
patients had the highest HBV-DNA levels (Table 2, Fig. 1).
Prevalence of Core Promoter and Precore Stop Codon Mutations in
Relation to HBeAg Status, HBV-DNA Detection, and Liver Disease.
A1896 was mostly found in HBeAg-negative patients, 37%
(47 of 128) versus 5% (5 of 95) in HBeAg-positive patients
(P , .001), whereas TA changes were present in similar
proportions of HBeAg-negative and HBeAg-positive patients,
65% (83 of 128) and 55% (52 of 95), respectively (Table 3).
Among the HBeAg-negative patients, 20% (26 of 128) had
A1896 only, 48% (62 of 128) had TA changes only, and 16%
(21 of 128) had both A1896 and TA changes (Table 3). The
prevalence of A1896 and TA changes was similar in groups I,
II, and III patients. HBV-DNA detection rates and mean
HBV-DNA levels were comparable in HBeAg-negative pa-
tients with or patients without A1896, and in patients with or
without TA changes.
Among the HBeAg-positive patients, there was a progres-
sive increase in the prevalence of TA changes as the liver
disease advances (P 5 .003). HBV-DNA detection rates were
similar in HBeAg-positive patients with or without TA
changes but HBV-DNA levels were significantly lower in
patients with TA changes, log mean HBV-DNA levels being
7.30 6 0.94 versus 8.88 6 0.88, (P , .001).
HBV Genotypes in Relation to HBeAg Status and Core Promoter
and Precore Stop Codon Mutations. Among the 223 patients with
detectable HBV DNA by PCR, HBV genotypes with C1858
and T1858 were present in 118 (53%) and 105 (47%)
patients, respectively. The distribution of HBV genotypes
with C1858 and T1858 among the HBeAg-positive (57% vs.
43%) and the HBeAg-negative (50% vs. 50%) patients was
similar. A1896 was exclusively found in patients with T1858,
73% (47 of 64) vs. 0% (0 of 64) HBeAg-negative patients with
C1858 (P , .001) (Table 4). In contrast, TA changes could be

















Group I 41 39 6 12 29 (71)* 35 (85)† 8.51 6 1.30‡
Group II 47 168 6 172 40 (85)§ 42 (89) 7.93 6 1.10
Group III 19 86 6 79 14 (74) 18 (95)\ 7.26 6 0.76
All 107 101 6 130 83 (78)¶ 95 (89)** 8.02 6 1.20††
HBeAg positive
Group I 153 34 6 12 11 (7)* 64 (42)† 6.42 6 0.38‡
Group II 54 152 6 175 25 (46)§ 40 (74) 7.37 6 0.82
Group III 36 78 6 52 16 (44) 24 (67)\ 6.86 6 0.58









FIG. 1. Box-plot analysis of serum HBV-DNA levels in relation to HBeAg
and clinical status. The boxes represent the second and third quartile and the
‘‘whiskers’’ extend from the lowest to the highest HBV-DNA levels in each
group of patients. Gp I, noncirrhotic patients with normal ALT levels; GP II,
noncirrhotic patients with elevated ALT levels; Gp III, patients with clinical
cirrhosis.







No. (%) of Patients With
A1896 Only A1896 1 TA TA Only No Change
HBeAg positive
Group I 35 2 (6) 0 (0) 9 (26) 24 (69)
Group II 42 1 (2) 1 (2) 26 (62) 14 (33)
Group III 18 0 (0) 1 (6) 15 (83) 2 (11)
All 95 3 (3) 2 (2) 50 (53) 40 (42)
HBeAg negative
Group I 64 9 (14) 9 (14) 36 (56) 10 (16)
Group II 40 13 (33) 6 (15) 16 (40) 5 (13)
Group III 24 4 (17) 6 (25) 10 (42) 4 (17)
All 128 26 (20) 21 (16) 62 (48) 19 (15)
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detected in patients with T or C at nucleotide 1858 and were
more common among those with C1858, 81% (52 of 64) vs.
48% (31 of 64) of HBeAg-negative patients with T1858,
(P , .001).
Other Mutations in the Core Promoter and Precore Regions. A
variety of other mutations were found in the core promoter
and precore regions (Table 5). The most common core
promoter mutations included deletions (7-20 base pairs
spanning nucleotide positions 1752-1777) in 5 patients, and
a double nucleotide substitution of C with T and G with A at
positions 1766 and 1768 in 16 patients. Of the latter 16
patients, all had concomitant T1762/A1764 changes, 10 were
HBeAg negative, 7 (44%) had detectable HBV DNA using
bDNA assay, and 7 had evidence of liver disease.
A precore start codon mutation was found in 9 patients, all
of whom were HBeAg negative, all had evidence of liver
disease, 7 (78%) had detectable HBV-DNA by bDNA assay.
Other mutations in the precore region included a G to A
change at nucleotide 1898 in 32 patients (14%), of whom 17
were HBeAg negative. All 32 patients had HBV genotypes
with C1858, none had A1896, and 28 (88%) had TA changes.
A1898 was more often found in patients with cirrhosis, 20%
(11 of 55) vs. 7% (21/295) in group I and II patients (P 5
.006). Another common mutation involved a G to A change
at nucleotide 1899 detected in 28 patients (13%), of whom 21
were HBeAg negative. Twenty-one patients had HBV geno-
types with T1858, and 7 had C1858. Twelve patients had
A1896 and 19 had TA changes. A1899 was also more
common in patients with clinical cirrhosis: 24% (13 of 55)
versus 5% (15 of 295) in groups I and II patients (P , .001).
DISCUSSION
In this study, we found that 69% of a consecutive series of
350 Chinese patients with chronic HBV infection seen by a
single hepatologist in Hong Kong were HBeAg negative. This
is higher than the 56% prevalence in a previously reported
series of 224 patients in Hong Kong.28 Several factors may
have contributed to the difference in prevalence of HBeAg in
these two series. First, patients in the current series were
older, mean age 42 versus 35 years in the previous series.
Second, the current study enrolled patients from the Hepatitis
as well as Hepatology Clinics (where patients with clinical
cirrhosis were seen), whereas the previous study enrolled
patients from the Hepatitis Clinic only. Finally, although both
studies excluded HBeAg-positive patients who were participat-
ing in clinical trials on antiviral therapy, it is possible that a
higher percent of HBeAg-positive patients were enrolled into
antiviral trials in 1998 than in 1987 when interferon was the
only treatment being evaluated. However, review of the clinic
records showed that only 4% of the patients seen in the
Hepatitis and Hepatology Clinics at the Prince of Wales
Hospital in the past 2 years were enrolled in antiviral trials. A
population study is needed to determine if there is a genuine
increase in the proportion of HBeAg-negative patients among
patients with chronic HBV infection in Hong Kong.
Of the 243 HBeAg-negative patients, 37% had clinical/
biochemical evidence of liver disease, of whom 46% had
detectable serum HBV DNA using bDNA assay. Thus, overall,
17% of HBeAg-negative patients (or 12% of the entire cohort)
fulfilled the definition of e2CHB (HBsAg positive, HBeAg
negative, serum HBV DNA detected by non-PCR assay, and
clinical/biochemical evidence of liver disease). However, this
figure may be a gross underestimate of the true prevalence of
e2CHB in Hong Kong because some HBeAg-negative pa-
tients may have fluctuating ALT levels and/or intermittent
detection of serum HBV DNA using the bDNA assay, which
has a detection limit of 7 3 105 viral equivalents/mL. In
addition, some HBeAg negative patients may have active liver
disease on histology despite normal ALT levels and undetect-
able serum HBV DNA especially when these tests were
















T1858 105 29 (28) 23 (22) 24 (22) 29 (28)
HBeAg1 41 3 (7) 2 (5) 14 (34) 22 (54)
HBeAg2 64 26 (40) 21 (33) 10 (16) 7 (11)
C1858 118 0 0 88 (75) 30 (25)
HBeAg1 54 0 0 36 (67) 18 (33)
HBeAg2 64 0 0 52 (81) 12 (19)
TABLE 5. Other Mutations in the HBV Core Promoter and Precore Regions in Relation to HBeAg and Clinical Status
No. of
Patients
No. (%) of Patients With
Core Promoter Mutations
No. (%) of Patients With
Precore Mutations
Deletion T1766/A1768 Start Codon A1898 A1899
HBeAg positive
Group I 35 0 (0) 2 (6) 0 (0) 4 (11) 2 (6)
Group II 42 1 (2) 1 (2) 0 (0) 6 (14) 1 (2)
Group III 18 0 (0) 3 (17) 0 (0) 5 (28) 4 (22)
All 95 1 (1) 6 (6) 0 (0) 15 (16) 7 (7)
HBeAg negative
Group I 64 4 (6) 7 (11) 0 (0) 7 (11) 6 (9)
Group II 40 0 (0) 2 (5) 6 (15) 4 (10) 6 (15)
Group III 24 0 (0) 1 (4) 3 (13) 6 (25) 9 (38)
All 128 4 (3) 10 (8) 9 (7) 17 (13) 21 (16)
Total* 223 5 (2) 16 (7)† 9 (4) 32 (14)‡ 28 (13)§
*Patients who were PCR positive.
†All 16 had concomitant T1762/A1764 changes.
‡All had C1858, 28 had concomitant T1762/A1764, none had A1896.
§7 had C1858, 21 had T1858, 19 had concomitant T1762/A1764 changes, 12 also had A1896.
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assessed on one occasion only. We acknowledge that popula-
tion studies are necessary to determine the true prevalence of
e2CHB. Nevertheless, the results of this study indicate that
e2CHB is not uncommon outside the Mediterranean basin.
Because of the high HBV carrier rate in Asia, the absolute
number of Asian patients with e2CHB may be significantly
higher than that in the Mediterranean countries.
We found that only 37% of our HBeAg-negative patients
had the precore stop codon mutation A1896 in contrast to
patients in Italy where the vast majority of patients with
e2CHB have A1896. The low prevalence of A1896 among
Chinese patients is related to the codominance of HBV
genotypes that have T or C at nucleotide 1858. In accordance
with our previous studies, A1896 was not detected in any
patient with HBV genotypes that have C1858. Even among
patients with T1858, only 73% of our HBeAg-negative
patients had A1896 underscoring the fact that e2CHB may
be a heterogenous condition and is not invariably associated
with precore HBV mutant. Approximately two thirds of our
HBeAg-negative patients had core promoter mutations (T1762/
A1764) that had been shown to decrease HBeAg production.
As in our previous report,15 the TA changes were more often
found in patients with HBV genotypes that have C1858,
which preclude the development of the precore stop codon
mutation. The finding of a high prevalence of TA changes in
HBeAg-positive patients is not surprising because we have
previously shown that these changes may precede HBeAg
seroconversion by 5 years.
Several studies reported an association between severity of
liver disease and the common core promoter (T1762/A1764)
and precore (A1896) mutations.7,9,29-31 More recently, there
have also been reports incriminating the T1762/A1764 muta-
tions in hepatocarcinogenesis.32,33 In this study, the preva-
lence of A1896 and T1762/A1764 changes was similar in the
three groups of HBeAg-negative patients confirming our
previous reports15 of a lack of correlation between these
mutations and liver disease. The high prevalence (61%) of
T1762/A1764 changes in our patients, none of whom had
hepatocellular carcinoma, and our previous observation of
patients who remained tumor-free up to 7 years after the
detection of these changes15 do not support a role of
T1762/A1764 core promoter mutations in hepatocarcinogen-
esis. Another double mutation (T1766/A1768) in the core
promoter region had been previously reported in a patient
with fulminant hepatitis.34 These changes were detected in
7% of our patients and were found in all three groups of
patients. We found that the only mutations that appeared to
be associated with more severe liver disease involved codon
29 in the precore region (G to A, nucleotide 1898 and G to A,
nucleotide 1899). Other investigators have also reported an
association between severity of liver disease and A1899.7,35 In
vitro studies suggested that precore and core promoter
mutations may enhance HBV replication thus accounting for
increased pathogenicity.16,17,19 We found no difference in
the rate of HBV-DNA detection or HBV-DNA levels among
HBeAg-negative patients with or without precore stop codon
mutation. Although a higher percent of HBeAg-negative
patients with TA changes had detectable serum HBV DNA,
the HBV-DNA levels were similar in patients with and
without core promoter changes.
As a group, the HBeAg-negative patients were less likely to
have detectable serum HBV DNA especially when tested by a
non-PCR based assay and had lower HBV-DNA levels. These
findings were true for the vast majority of group I patients
who had normal ALT levels. In contrast, group I HBeAg-
positive patients had the highest HBV-DNA levels. Thus, the
clinical significance of HBsAg-positive carriers with normal
ALT levels may be very different depending on the HBeAg
status. Unlike patients with normal ALT levels, 46% of our
HBeAg negative patients who had elevated ALT levels or
clinical cirrhosis had detectable serum HBV DNA by bDNA
assay with levels that were comparable with those in the
HBeAg-positive patients suggesting that antiviral therapy
may be beneficial in these patients. Interferon has been
shown to be effective in suppressing HBV replication and in
normalizing ALT levels in patients with e2CHB but relapse is
common after cessation of treatment.20-22 Recently, lamivu-
dine has been reported to be effective in inducing biochemi-
cal, virological, and histological response in anti-HBe–
positive patients with chronic hepatitis.36 Most of the patients
in that study were Italians and Greeks. Whether these
encouraging results can be applied to Asian patients and
whether the response can be maintained after withdrawal of
lamivudine remain to be determined.
In summary, we found that e2CHB may be present in up to
20% of HBeAg-negative patients seen in a tertiary referral
center in Hong Kong. These patients had HBV-DNA levels
that were comparable with HBeAg-positive patients suggest-
ing that they may benefit from antiviral therapy. Contrary to
e2CHB seen in Mediterranean countries, only 37% of our
patients had the precore stop codon mutant. Thus, it is
unclear if Asian patients with e2CHB have the same natural
course and response to treatment as the Italian and Greek
patients. Given the high HBV carrier rate in Asia, population
studies to determine the true prevalence of e2CHB in Asia
and its natural course and response to treatment are urgently
needed.
Acknowledgment: The authors are grateful to Dr. Lorraine
Comanor at Chiron Corp. for running the bDNA assays and
to Jessica Ching at the Prince of Wales Hospital for assistance
with statistical analyses.
REFERENCES
1. Hoofnagle JH, Dusheiko GM, Seeff LB, Jones EA, Waggoner JG, Bales ZB.
Seroconversion from hepatitis B e antigen to antibody in chronic type B
hepatitis. Ann Intern Med 1981;94:744-748.
2. Realdi G, Alberti A, Rugge M, Bortolotti F, Rigoli AM, Tremolada F, Ruol
A. Seroconversion from hepatitis B e antigen to anti-HBe in chronic
hepatitis B virus infection. Gastroenterology 1980;79:195-199.
3. Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis
of liver disease, nuclear HBcAg, DNA viral replication, and hepatitis B
virus DNA in liver and serum of HBeAg vs anti-HBe positive carriers of
hepatitis B virus. HEPATOLOGY 1983;3:656-662.
4. Lok ASF, Hadziyannis S, Weller IVD, Karvountzis MV, Monjardino J,
Karayiannis P, Montano L, et al. Contribution of low level HBV
replication to continuing inflammatory activity in patients with anti-HBe
positive chronic hepatitis B virus infection. Gut 1984;25:1283-1287.
5. Bonino F, Rosina F, Rizzetto M. Chronic hepatitis in HBsAg carriers with
serum HBV DNA and anti-HBe. Gastroenterology 1986;90:1268-1273.
6. Brunetto MR, Stemler M, Schodel F, Will H, Ottobrelli A, Rizzetto M,
Verme G, et al. Identification of HBV variants which cannot produce
precore derived HBeAg and may be responsible for severe hepatitis. Ital J
Gastroenterol 1989;21:151-154.
7. Carman WF, Hadziyannis S, McGarvey MJ, Jacyna MR, Karayiannis P,
Makris A, Thomas HC. Mutation preventing formation of hepatitis B e
antigen in patients with chronic hepatitis B infection. Lancet 1989;ii:588-
590.
8. Akahane Y, Yamanaka T, Suzuki H, Sugai Y, Tsuda F, Yotsumoto S, Omi S,
et al. Chronic active hepatitis with hepatitis B virus DNA and antibody
against e antigen in the serum. Disturbed synthesis and secretion of e
HEPATOLOGY Vol. 31, No. 3, 2000 CHAN ET AL. 767
antigen from hepatocytes due to a point mutation in the precore region.
Gastroenterology 1990;99:1113-1119.
9. Okamoto H, Yotsumoto S, Akahane Y, Yamanaka T, Miyazaki Y, Sugai Y,
Tsuda F, et al. Hepatitis B viruses with precore region defects prevail in
persistently infected hosts along with seroconversion to the antibody
against e antigen. J Virol 1990;64:1298-1303.
10. Laras A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical
significance of hepatitis B virus precore gene translation initiation
mutations in e antigen-negative patients. J Viral Hepatitis 1998;5:241-
248.
11. Lok ASF, Akarca U, Greene S. Mutations in the pre-core region of
hepatitis B virus serve to enhance the stability of the secondary structure
of the pre-genome encapsidation signal. Proc Natl Acad Sci U S A
1994;91:4077-4081.
12. Okamoto H, Tsuda F, Akahane Y, Sugai Y, Yoshiba M, Moriyama K,
Tanaka T, et al. Hepatitis B virus with mutations in the core promoter for
an e antigen-negative phenotype in carriers with antibody to e antigen. J
Virol 1994;68:8102-8110.
13. Kidd-Ljunggren K, Oberg M, Kidd AH. Hepatitis B virus X gene 1751 to
1764 mutations: implications for HBeAg status and disease. J Gen Virol
1997;78:1469-1478.
14. Kurosaki M, Enomoto N, Asahina Y, Sakuma I, Ikeda T, Tozuka S, Izumi
N, et al. Mutations in the core promoter region of hepatitis B virus in
patients with chronic hepatitis B. J Med Virol 1996;49:115-123.
15. Chan HLY, Hussain M, Lok ASF. Different hepatitis B virus genotypes are
associated with different mutations in the core promoter and precore
regions during hepatitis B e antigen seroconversion. HEPATOLOGY 1999;
29:976-984.
16. Buckwold VE, Xu Z, Chen M, Yen TSB, Ou JH. Effects of a naturally
occurring mutation in the hepatitis virus basal core promoter on precore
gene expression and viral replication. J Virol 1996;70:5845-5851.
17. Scaglioni PP, Melegari M, Wands JR. Biological properties of hepatitis B
viral genomes with mutations in the precore promoter and precore open
reading frame. Virology 1997;233:374-381.
18. Moriyana K, Okamoto H, Tsuda F, Mayumi M. Reduced precore
transcription and enhanced core-pregenome transcription of hepatitis B
virus DNA after replacement of the precore-core promoter with se-
quences associated with e antigen-seronegative persistent infections.
Virology 1996;226:269-280.
19. Gunther S, Piwon N, Will H. Wild type levels of pregenomic RNA and
replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B
virus with C(1653)-T, A(1762)-T, and G(1764)-A mutation in the core
promoter. J Gen Virol 1998;79:365-380.
20. Brunetto MR, Giarin M, Saracco G, Oliveri F, Calvo P, Capra G, Radone
A, et al. Hepatitis B virus unable to secrete e antigen and response to
interferon in chronic hepatitis B. Gastroenterology 1993;105:845-850.
21. Pastore G, Sanantonio T, Milella M, Monno L, Mariano N, Moschetta R,
Pollice L. Anti-HBe positive chronic hepatitis B with HBV DNA in the
serum, response to a 6 month course of lymphoblastoid interferon. J
Hepatol 1992;14:221-225.
22. Fattovich G, Farci P, Rugge M, Brollo L, Mandas A, Pontisso P, Giustina
G, et al. A randomized controlled trial of lymphoblastoid interferon-
alpha in patients with chronic hepatitis B lacking HBeAg. HEPATOLOGY
1992;15:584-589.
23. The Incident Investigation Team and others. Transmission of hepatitis B
to patients from four infected surgeons without hepatitis B e antigen. N
Engl J Med 1997;336:178-184.
24. Lindh M, Andersson AS, Gusdal A. Genotypes, nt 1858 variants, and
geographic origin of hepatitis B virus—large-scaled analysis using a new
genotyping method. J Infect Dis 1997;175:1285-1293.
25. Mangia A, Chung YH, Hoofnagle JH, Birkenmeyer L, Mushahwar I,
DiBisceglie AM. Pathogenesis of chronic liver disease in patients with
chronic hepatitis B virus infection without serum HBeAg. Dig Dis Sci
1996;41:2447-2452.
26. Li JS, Tong SP, Wen YM, Vitvitski L, Zhang Q, Trepo C. Hepatitis B virus
genotype A rarely circulates as an HBe-minus mutant: possible contribu-
tion of a single nucleotide in the precore region. J Virol 1993;67:5402-
5410.
27. Rodriguez-Frias F, Buti M, Jardi R, Cotrina M, Viladomiu L, Esteban R,
Guardia J. Hepatitis B virus infection: precore mutants and its relation to
viral genotypes and core mutations. HEPATOLOGY 1995;22:1641-1647.
28. Lok ASF, Lai CL, Wu PC, Leung EKY, Lam TS. Spontaneous hepatitis B e
antigen to antibody seroconversion and reversion in Chinese patients
with chronic hepatitis B virus infection. Gastroenterology 1987;92:1839-
1843.
29. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutation in the
precore region of hepatitis B virus DNA in patients with fulminant and
severe hepatitis. N Engl J Med 1991;324:1699-1704.
30. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B
virus mutant associated with an epidemic of fulminant hepatitis. N Engl
J Med 1991;324:1705-1709.
31. Sato SS, Suzuki K, Akahane Y, Akamatsu K, Akiyama K, Yunomura K,
Tsuda F, et al. Hepatitis B virus strains with mutations in the core
promoter in patients with fulminant hepatitis. Ann Intern Med 1995;122:
241-248.
32. Fang ZL, Ling R, Wang SS, Nong J, Huang CS, Harrison TJ. HBV core
promoter mutations prevail in patients with hepatocellular carcinoma
from Guangxi, China. J Med Virol 1998;56:18-24.
33. Baptista M, Kramvis A, Kew MC. High prevalence of 1762T 1764A
mutations in the basic core promoter of hepatitis B virus isolated from
black Africans with hepatocellular carcinoma compared with asymptom-
atic carriers. HEPATOLOGY 1999;29:946-953.
34. Baumert TF, Rogers SA, Hasegawa K, Liang TJ. Two core promoter
mutations in a hepatitis B virus strain associated with fulminant hepatitis
result in enhanced viral replication. J Clin Invest 1996;98:2268-2276.
35. Tillmann H, Trautwein C, Walker D, Michitaka K, Kubicka S, Boker K,
Manns M. Clinical relevance of mutations in the precore genome of the
hepatitis B virus. Gut 1995;37:568-573.
36. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin R,
Hawley S, et al. Efficacy of lamivudine in patients with hepatitis B e
antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic
hepatitis B. HEPATOLOGY 1999;29:889-896.
768 CHAN ET AL. HEPATOLOGY March 2000
